Overview

Fruquintinib CYP3A Inhibitor and Inducer Study

Status:
Completed

Trial end date:
2020-10-18

Target enrollment:

Participant gender:

Summary

A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Hutchison Medipharma Limited

Collaborator:

Covance

Treatments:

Itraconazole
Rifampin